Home › Cystic Fibrosis › NCT07437105

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Key Inclusion Criteria:

* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
* A total body weight of more than (\>) 50 kg
* Male and Female participants of non-childbearing potential

Key Exclusion Criteria:

* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
* Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.

About the study

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272 in combination with deutivacaftor (D-IVA) with or without tezacaftor (TEZ) in healthy subjects.

What is being tested

• VX-272 (drug)
• Placebo (drug)
• Tezacaftor (drug)
• Deutivacaftor (drug)

Sponsor: Vertex Pharmaceuticals Incorporated · Participants: 160 · Started: Feb 25, 2026

Contact the study team

• Medical Information · Phone: 617-341-6777

Official record on ClinicalTrials.gov — NCT07437105

Locations in the U.S.

Conditions

• Cystic Fibrosis

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.